Noxopharm reports anti-cancer effects of Veyonda

Sydney anti-cancer treatment company Noxopharm (ASX: NOX) has reported anti-cancer effects of its Veyonda treatment in a small group of patients suffering advanced prostate cancer. The 14 patients’ cancers were metastatic and they had exhausted all treatment options when given Veyonda in association with low-dosage radiation in a single lesion. After six months, cancer progression…

LBT Innovations makes its first instrument sale in the EU

Medical technology and equipment developer LBT Innovations (ASX: LBT) has made its first European sale of its APAS Independence laboratory instrument (pictured). The sale was made to one of the largest clinical laboratories in the EU, Labor Dr Wisplinghoff, which employes more than 40 medical specialists. Laboratory director Professor Hilmar Wilplinghoff joined LBT Innovations CEO…

Our ability to manufacture minerals could transform the gem market, medical industries and even help suck carbon from the air

By Anita Parbhakar-Fox, Senior Research Fellow in Geometallurgy/Applied Geochemistry, The University of Queensland and Paul Gow, Principal Research Fellow, The University of Queensland Last month, scientists uncovered a mineral called Edscottite. Minerals are solid, naturally occurring substances that are not living, such as quartz or haematite. This new mineral was discovered after an examination of the…

Canberra-esque madness kills the SME-focused innovation patent system

Comment by Peter Roberts Parliament has passed legislation killing the low cost innovation patent system, bowing to arguments from the Productivity Commission. Legislation killing the patent was passed by the Senate last week and followed an essentially economically-focused review that lacked transparency. This is yet another victory in a long list of destructive wins by…